Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008 – present)

Bibliography

• Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;42:1-40
   PubMed Web of Science ®Google Scholar
• Chahrour O, Cairns D, Omran Z. Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev in Med Chem 2012;12:399-411
   PubMed Web of Science ®Google Scholar
• Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010). Expert Opin Ther Patents 2012;22:223-52
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-6
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Disc 2011;10:811-12
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Disc 2012;11:103-4
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. Preparation of benzoylpyrazolo[3,4-b]pyridines and analogs as cyclin dependent kinase inhibitors. WO9930710; 1999
   Google Scholar
• Misra RN, Xiao H, Rawlins DB, 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-difluorophenacyl analogues. Bioorg Med Chem Lett 2003;13:2405-8
   PubMed Web of Science ®Google Scholar
• Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov Today 2007;12:149-55
   PubMed Web of Science ®Google Scholar
• Langdon SR, Ertl P, Brown N. Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol Inf 2010;29:366-85
   PubMed Web of Science ®Google Scholar
• Sun H, Tawa G, Wallqvist A. Classification of scaffold-hopping approaches. Drug Discov Today 2012;17:310-24
   PubMed Web of Science ®Google Scholar
• Array BioPharma. Pyrazolopyridine derivatives and their pharmaceutical compositions as CHK1 and CHK2 kinase inhibitors for the treatment of various diseases and preparation thereof. WO2009089359; 2009
   Google Scholar
• Array BioPharma. Pyrrolo[2,3-b]pyridines as CHK1 and CHK2 kinase inhibitors for the treatment of various diseases and preparation thereof. WO2009089352; 2009
   Google Scholar
• Array BioPharma. Preparation of pyrrolopyridines as checkpoint kinase CHK1 and/or CHK2 inhibitors. WO2009140320; 2009
   Google Scholar
• Array BioPharma/Genentech. Preparation of pyrazolopyridines as tyrosine kinase inhibitors. WO2009033084; 2009
   Google Scholar
• Array BioPharma/Genentech. Heterobicyclic pyrazole compounds as Met tyrosine kinase inhibitors and their preparation and use. WO2007103308; 2007
   Google Scholar
• Array BioPharma/Genentech. Pyrazole[3,4-b]pyridine Raf. WO2009111278; 2009
   Google Scholar
• Wenglowsky S, Ren L, Ahrendt KA, Pyrazolopyridine inhibitors of B-RafV600E. Part 1: the development of selective, orally bioavailable and efficacious inhibitors. ACS Med Chem Lett 2011;2:342-7
   PubMed Web of Science ®Google Scholar
• Wenglowsky S, Moreno D, Rudolph J, Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing. Bioorg Med Chem Lett 2012;22:912-15
   PubMed Web of Science ®Google Scholar
• Wenglowsky S, Ahrendt KA, Buckmelter AJ, Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. Bioorg Med Chem Lett 2011;21:5533-7
   PubMed Web of Science ®Google Scholar
• Array BioPharma/Genentech. N-Pyrrolo[2,3-b]pyridinyl benzamide derivatives as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2009111278; 2009
   Google Scholar
• Array BioPharma/Genentech. Imidazo[4,5-b]pyridine derivatives used as Raf inhibitors and their preparation and use in the treatment of diseases. WO2009111277; 2009
   Google Scholar
• Array BioPharma/Genentech. Preparation of 1H-pyrazolo[1,5-a]pyrimidine compounds useful for inhibiting Raf kinase. WO2011025951; 2011
   Google Scholar
• Array BioPharma/Genentech. 1H-Pyrazolo[3,4-b]pyridine compounds for inhibiting Raf kinase. WO2011025968; 2011
   Google Scholar
• Arqule. Preparation of substituted pyrazolo[3,4-b]pyridine compounds useful in the treatment of proliferative disorders such as cancer. WO2010078427; 2010
   Google Scholar
• Sunesis. Preparation of pyridinonyl PDK1 inhibitors. WO2008005457; 2008
   Google Scholar
• Heterocyclic compounds useful as PKD1 inhibitors. WO2011044157; 2008
   Google Scholar
• Cancer Research Technology Ltd. Morpholino-bicyclo-heteroaryl compounds as CHK1 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2008075007; 2007
   Google Scholar
• Matthews TP, Klair S, Burns S, Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 2009;52:4810-19
   PubMed Web of Science ®Google Scholar
• China Intellectual Property Law Office. Aromatic alkyne-indanecarboxamide derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of proliferative and inflammatory diseases. WO2012089106; 2012
   Google Scholar
• Esai. Diazaindole derivatives, their preparation and therapeutic use as inhibitors of c-Jun N-terminal kinase. WO2010015803; 2010
   Google Scholar
• Exelixis. Preparation of pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-d]pyrimidine, and 3H-imidazo[4,5-b]pyridine derivatives as cyclin-dependent kinase (CDK) modulators. WO2010003133; 2010
   Google Scholar
• Genomics Institute of the Novartis Research Institute. Preparation of pyrrolo[2,3-b]pyridinecarboxamides as protein kinase inhibitors. WO2008144253; 2008
   Google Scholar
• Japan Tobacco. Preparation of nitrogen-containing spiro-ring compounds as Janus kinase (JAK) kinase inhibitors. WP2011013785; 2011
   Google Scholar
• Zerbini CAF, Lomonte ABV. Tofacitinib for the treatment of rheumatoid arthritis. Exp Rev Clin Immunol 2012;8:319-31
   PubMed Web of Science ®Google Scholar
• Merck Patent GMBH. Pyridinylimidazolone derivatives for inhibiting PI3 kinases and their preparation and use in the treatment of diseases. WO2011035855; 2011
   Google Scholar
• Nerviano Medical Sciences. Preparation of 1H-pyrazolo[3,4-b]pyridin-3-ylacrylamides as protein kinase B inhibitors. EP1980561; 2008
   Google Scholar
• Nerviano Medical Sciences. Preparation of 7-azaindol-3-ylacrylamides as AKT and Cdc7 kinase inhibitors. EP2070928; 2009
   Google Scholar
• Plexxikon. Preparation of N-(pyrazolopyridinyloxophenyl)propylsulfonamide derivatives for use as Raf kinase inhibitors. WO2010111527; 2010
   Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9
   PubMed Web of Science ®Google Scholar
• OSI Pharmaceuticals. Preparation of fused bicyclic heterocycles as kinase inhibitors. WO2011143646; 2011
   Google Scholar
• OSI Pharmaceuticals. Substituted pyrrolo[2,3-b]-pyridines and -pyrazines. WO2010059771; 2010
   Google Scholar
• SGX Pharmaceuticals. Preparation of pyrazolo[3,4-b]pyridine derivatives as kinase modulators. WO2008124850; 2008
   Google Scholar
• SGX Pharmaceuticals. Fused ring heterocycle compounds as kinase modulators and their preparation, pharmaceutical compositions and use in the treatment diseases mediated by kinase activity. WO2008124848; 2008
   Google Scholar
• SGX Pharmaceuticals. Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2008150914; 2008
   Google Scholar
• SGX Pharmaceuticals. Preparation of pyrazolo[3,4-b]pyridine derivatives as kinase modulators. WO2006015124; 2006
   Google Scholar
• Scripps Research Institute. Preparation of pyrazolylphenyl urea and carbamate compounds and analogs as kinase inhibitors. WO2010036316; 2010
   Google Scholar
• Vertex Pharmaceuticals. Preparation of pyrazolopyridine kinase inhibitors. WO2010011756; 2010
   Google Scholar
• Vertex Pharmaceuticals. Preparation of tri-cyclic pyrazolopyridine kinase inhibitors. WO2010011772; 2010
   Google Scholar
• Vertex Pharmaceuticals. 1H-Pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors and their preparation and use for the treatment of protein kinase-mediated diseases. WO2011094273; 2011
   Google Scholar
• Vertex Pharmaceuticals. 1H-Pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors and their preparation and use for the treatment of protein kinase-mediated diseases. WO2011094283; 2011
   Google Scholar
• Vertex Pharmaceuticals. Azaindoles useful as inhibitors of JAK and other protein kinases. WO2005095400; 2005
   Google Scholar
• Vertex Pharmaceuticals. Preparation of pyrazolopyridine kinase inhibitors. WO2010011762; 2010
   Google Scholar
• Vertex Pharmaceuticals. Crystal structure of Rho kinase I kinase domain and complexes thereof. US20090036654; 2009
   Google Scholar
• Vertex Pharmaceuticals. Preparation of tri-cyclic pyrazolopyridine kinase inhibitors. WO2010011768; 2010
   Google Scholar
• Vertex Pharmaceuticals. Azaindoles use as inhibitors or ROCK and other protein kinases. WO2005103050; 2005
   Google Scholar
• Vertex Pharmaceuticals. Preparation of [1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl or pyridin-2-yl derivatives as protein kinase C-theta inhibitors. WO2009073300; 2009
   Google Scholar
• Vertex Pharmaceuticals. Preparation of pyrazolopyridines as inhibitors of protein kinase. WO2010129668; 2010
   Google Scholar
• Merck. Preparation of pyrazolopyridinamines and analogs as EphA4 RTK inhibitors for treatment of neurological and neurodegenerative disorders and cancer. US20100113415; 2010
   Google Scholar
• Parmentier-Batteur S, Finger EN, Krishnan R, Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors. J Neurochem 2011;118:1016-31
   PubMedGoogle Scholar
• van Linden OP, Farenc C, Zoutman WH, Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase. Eur J Med Chem 2012;47:493-500
   PubMedGoogle Scholar
• Bristol-Myers Squibb. Azaindazoles as Btk kinase modulators and their preparation. WO2011019780; 2011
   Google Scholar
• Pierre Fabre Medicament. Preparation of pyrazolopyridine derivatives as ALK kinase inhibitors for treating cancer. WO2011045344; 2011
   Google Scholar
• GlaxoSmithKline. Inhibitors of AKT activity. WO2009032652; 2009
   Google Scholar
• Lin H, Yamashita DS, Zeng J, 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: substitution at 2-position of the core pyridine for ROCK1 selectivity. Bioorg Med Chem Lett 2010;20:673-8
   PubMedGoogle Scholar
• Lin H, Yamashita DS, Zeng J, 2,3,5-trisubstituted pyridines as selective AKT inhibitors. Part II: improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett 2010;20:679-83
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals does not discrimination between the two isoforms of GSK-3 in their patent applications: “Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of alpha and beta isoforms that are each encoded by distinct genes”
   Google Scholar
• Vertex Pharmaceuticals. Preparation of (pyrimidinyl)(pyrazolo[3,4-b]pyridinyl)amines and analogs as GSK-3 inhibitors. WO2004013140; 2004
   Google Scholar
• Vertex Pharmaceuticals. Preparation of aminopyridines and aminopyrimidines useful as inhibitors of protein kinases. WO2008057940; 2008
   Google Scholar
• Vertex Pharmaceuticals. Preparation of aminopyrimidines useful as inhibitors of protein kinases. WO2008077086; 2008
   Google Scholar
• Vertex Pharmaceuticals. Aminopyrimidines useful as inhibitors of protein kinases. WO2008112651; 2008
   Google Scholar
• Vertex Pharmaceuticals. Preparation of aminopyrimidines useful as inhibitors of protein kinases. WO2008112642; 2008
   Google Scholar
• Vertex Pharmaceuticals. Preparation of azolylaminopyridines as inhibitors of GSK3 protein kinases. WO2008112646; 2008
   Google Scholar
• Vertex Pharmaceuticals. Pyrimidines and pyridines useful as inhibitors of protein kinases. WO2009145814; 2009
   Google Scholar
• Vertex Pharmaceuticals. Process for preparing 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine and derivatives thereof. WO2009018415; 2009
   Google Scholar
• The University of Tokyo. Preparation of 2-[(1H-indol-3-yl)methylene]benzofuran-3(2H)-one derivatives and their azaindole analogs as selective pim-1 kinase inhibitors and anticancer agents. WO2011136319; 2011
   Google Scholar
• Nakano H, Saito N, Parker L, Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. J Med Chem 2012;55:5151-64
   PubMed Web of Science ®Google Scholar
• Nishiguchi GA, Atallah G, Bellamacina C, Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 2011;21:6366-9
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham. Preparation of quinoline derivatives as PI3 kinase inhibitors. WO2008144463; 2008
   Google Scholar
• SmithKline Beecham. Preparation of quinoline derivatives as PI3 kinase inhibitors. WO2008144464; 2008
   Google Scholar
• Knight SD, Adams ND, Burgess JL, Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010;1:39-43
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Benzopyrazole derivatives as PI3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2009147188; 2009
   Google Scholar
• GlaxoSmithKline. Preparation of 4-amino-1H-indazole compounds as inhibitors of PI3-kinases for treatment of asthma and COPD. WO2009147190; 2009
   Google Scholar
• Genentech. Preparation of indazole and benzo[d]isothiazole derivatives as MEK kinase inhibitors. WO2010003025; 2010
   Google Scholar
• Heald RA, Jackson P, Savy P, Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J Med Chem 2012;55:4594-604
   PubMedGoogle Scholar